On December 27, Sangamo Therapeutics (SGMO) stock price closed at $10.59, which is a ~1.58% decline from its prior day close of $10.76 on December 26, 2018. On December 26, Sangamo Therapeutics stock price grew ~7.71% to reach $10.76 from its prior day close of $9.99 on December 24, 2018.
The stock’s price on December 27 was a ~61% decline from its 52-week high of $27.5 on February 22, 2018. Sangamo hit its 52-week low of $9.00 on November 14, 2018.
In December 2018, Sangamo Therapeutics announced that the company administered its investigational in vivo genome editing therapy, SB-FIX, to the first patient for the treatment of hemophilia B. The company is conducting a phase 1/2 trial of SB-FIX for the evaluation of its safety and efficacy in the treatment of individuals with hemophilia B. The US FDA (Food and Drug Administration) has already granted an Orphan Drug and Fast Track designation to SB-FIX.
Of the eight analysts tracking Sangamo Therapeutics (SGMO) in December 2018, three of them recommended a “strong buy,” while two analysts recommended a “buy.” Three analysts recommended a “hold” rating. On December 28, Sangamo Therapeutics had a consensus 12-month target price of $22.71, which is a ~114.45% return on investment over the next 12 months.
In December 2018, of the 22 analysts tracking Spark Therapeutics (ONCE), ~59% of them recommended “buys,” while of the 11 analysts tracking Crispr Therapeutics (CRSP), ~64% of them recommended “buys.” Of the 24 analysts tracking bluebird bio (BLUE), ~71% of them recommended “buys.”
On December 28, Spark Therapeutics, Crispr Therapeutics, and bluebird bio had consensus 12-month target prices of $62.65, $63.72 and $180.24, respectively, which is a ~69.23%, ~141.27%, and $84.92% return on investment over the next 12 months.